FITC Conjugated Anti-Human CD33 Antibody [PSH04-96]

HA720197F

Product Type:	Recombinant Rabbit monoclonal IgG, primary antibodies
Species reactivity:	Human
Applications:	FC
Molecular Wt:	Predicted band size: 40 kDa
Clone number:	PSH04-96

Description: CD33 or Siglec-3 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67) is a transmembrane receptor expressed on cells of myeloid lineage. It is usually considered myeloid-specific, but it can also be found on some lymphoid cells. It binds sialic acids, therefore is a member of the SIGLEC family of lectins. CD33 can be stimulated by any molecule with sialic acid residues such as glycoproteins or glycolipids. Upon binding, the immunoreceptor tyrosine-based inhibition motif (ITIM) of CD33, present on the cytosolic portion of the protein, is phosphorylated and acts as a docking site for Src homology 2 (SH2) domain-containing proteins like SHP phosphatases. This results in a cascade that inhibits phagocytosis in the cell.

Conjugate: FITC-conjugated

Immunogen: Recombinant protein within human CD33 aa 1-282 / 364 (P20138).

Positive control: Human peripheral blood.

Subcellular location: Cell membrane; Peroxisome.

Database links: SwissProt: P20138 Human

Recommended Dilutions:

FC 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Storage Buffer: Supplied in phosphate-buffered solution, pH 7.2, containing 0.2% ProClean 950 and BSA.

Storage Instruction: Store at 2℃ to 8℃. Avoid repeated freeze / thaw cycles.

Purity: Protein A affinity purified.

Images



Fig1: Flow cytometric analysis of human peripheral blood labelling Human CD33 (HA720197F, FITC).

Note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE".

Background References

1. Albinger N et al. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. Blood Cancer J. 2022 Apr
2. Willier S et al. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. Blood. 2021 Feb